Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous mesenchymal stem cells plus biomaterial vs autologous bone block grafting for jaw bone regeneration
2018-001227-39Phase 2Completed
- Sponsor
- University of Bergen
- Start
- Nov 2019
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised trial of autologous mesenchymal stem cells in Jawbone defect, Alveolar bone atrophy (ABL) and Bone-related disorders (2 arms), sponsored by University of Bergen. Primary endpoint: Linear change in bone width. Started Nov 2019; status: completed.
02
Drugs
autologous mesenchymal stem cells
03
Conditions
Jawbone defectAlveolar bone atrophy (ABL)Bone-related disorders
Beyond the preview
Go deeper on 2018-001227-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001227-39.